FOSTER CITY, Calif., March 19, 2024 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide ...
FOSTER CITY, Calif., April 28, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...
Adela's tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & neck cancer, regardless of HPV status The test identified recurrences in ...
Canadian newcomer Adela has shown that its test for detecting the faint traces of cancer in the bloodstream could spot 12 different types of the disease, including many in their early stages when they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback